CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01116193
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:48.293761+00:00
Published At: 2017-09-14T00:00:00+00:00
Record Updated At: 2017-09-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Leukemia, Lymphoid", "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-09-14"
protocolSection.identificationModule.nctId: "NCT01116193"
protocolSection.identificationModule.officialTitle: "A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid \u00ae) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.